Pembrolizumab Adjuvant in Patients With Early-stage Triple Negative Breast Cancer With Residual Disease After Neoadjuvant Pembrolizumab Plus Chemotherapy

NCT07486687 · clinicaltrials.gov ↗

PHASE3

Phase

NOT_YET_RECRUITING

Status

1000

Enrollment

OTHER

Sponsor class

Conditions

Triple Negative Breast Cancer (TNBC), Early Setting
Early Stage Triple-Negative Breast Carcinoma
Triple -Negative Breast Cancer
Breast Cancer Stage II
Breast Cancer Stage III

Interventions

DRUG: Standard of care plus pembrolizumab
DRUG: Standard of care (capecitabine or olaparib)

Sponsor

The Netherlands Cancer Institute

Collaborators

[object Object]
[object Object]
[object Object]
[object Object]